Personalizirovannyy podkhod k rezhimu insulinoterapii - est' li mesto strakhu gipoglikemiy?
- 作者: Volkova N.I1, Porksheyan M.I1
-
隶属关系:
- 期: 编号 5 (2015)
- 页面: 28-31
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287808
- ID: 287808
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Currently, much attention is paid to the quality of life of the patient as one of the indicators for assessing the effectiveness of different modes of treatment of diabetes mellitus. The main factor that reduces the quality of life of patients receiving insulin therapy, is the fear of hypoglycemia. Fear of hypoglycemia leads to severe psychological and social maladjustment and reduces adherence to the treatment. Thus, when selecting regimen of insulin therapy, not only the incidence of hypoglycemia, but its impact on quality of life, including fear of hypoglycemia, should be considered.
全文:
参考
- Speight J, Reaney M.D., Barnard K.D. Not all roads lead to Rome - a review of quality of life measurement in adults with diabetes. Diabetic Medicine. 2009;26:315-27.
- Anderson R.J., Freedland K.E., Clouse R.E., Lustman P.J. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069-78.
- Peyrot M, Rubin R.R., Chen X., Frias J.P. Associations between improved glucose control and patient-reported outcomes after initiation of insulin pump therapy in patients with type 2 diabetes mellitus. Diabetes Technol. Ther. 2011;13:471-76
- Шишкова Ю.А., Суркова Е.В., Мотовилин О.Г., Майоров А.Ю. Качество жизни при сахарном диабете: определение понятия, современные подходы к оценке, инструменты для исследования. Сахарный диабет. 2011; 3:70-5.
- Патракеева Е. М.,Дуничева М. Н.,Залевская А. Г. Страх гипогликемии у пациентов с сахарным диабетом 1 типа. Сахарный диабет. 9. 2014;2:66-75.
- Волкова Н.И., Давиденко И.Ю. Липогипертрофии у больных, получающих инсулинотерапию: современное состояние проблемы. Сахарный диабет. 2011;2:86-9.
- Riddle M.C., Rosenstock J., Vlajnic A., Gao L. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes. Metab. 201;16(5):396-402.
- Polonsky W.H.,Thompson S., Wei W., Riddle M.C., Chaudhari S., Jackson J., Bruno A.S. Greater fear of hypoglycaemia with premixed insulin than with basal-bolus insulin glargine and glulisine: patient-reported outcomes from a 60-week randomised study. Diabetes Obes. Metab. 2014;16(11):1121-27. Jacobson A.M., de Groot M., Samson J.A. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care. 1994;1:267-74.
- Secnik Boye K., Matza L.S., Oglesby A., Malley K., Kim S., Hayes R.P., Brodows R. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual. Life Outcomes. 2006;4:80.
- Vinik A.I., Zhang Q. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care. 2007;30:795-800.
- Swinnen S.G., Dain M.P., Aronson R., Davies M., Gerstein H.C., Pfeiffer A.F., Snoek F.J., Devries J.H., Hoekstra J.B., Holleman F. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type
- diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 2010; 33:1176-78.
- Bradley C., El-Haschimi K. Treatment satisfaction in patients with type 2 diabetes: basal insulin plus oral agents versus twice-daily premixed insulin alone - analyses by country. Diabet Med. 2006;23(1):361(P1010).
- Wolffenbuttel B.H., van Ouwerkerk B.M., Veldhuyzen B.F., Geelhoed-Duijvestijn P.H., Jakobsen G., van Doorn L.G. Comparative effects of two different multiple njection regimens on blood glucose control and patient acceptance in type 1 diabetes. Diabet. Med. 1990;7:695-99.
- Bretzel R.G., Nuber U., Landgraf W., Owens D.R., Bradley C., Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypogly-caemic agents (APOLLO): an open randomised controlled trial. Lancet. 2008;371:1073-84.
补充文件
